Hum. Reprod. Advance Access published online on March 11, 2004
Human Reproduction, doi:10.1093/humrep/deh183
© 2004 by European Society of Human Reproduction and Embryology
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Assisted Conception Unit, Guy’s and St. Thomas’ Hospital NHS Trust, London, UK
BACKGROUND: This study was designed to assess the value of using a gonadotrophin-releasing hormone (GnRH) agonist prior to exogenous steroid supplementation for endometrial preparation in frozen-thawed embryo replacement (FER) cycles. METHODS: A prospective randomized trial of 234 patients undergoing FER cycles was conducted. The study population was randomly divided into two groups according to a computer-generated list. In group A (n = 117), a daily dose of 6 mg of oral estradiol valerate was initiated on menstrual day 1 following pituitary suppression using 400 mcg buserelin acetate daily. In group B (n = 117), the same dose of estradiol valerate was initiated on day 1 of bleeding without prior GnRH agonist therapy. In both groups, ovulation monitoring was not undertaken and progesterone pessaries (800 mg daily) were administrated when the endometrial thickness had reached 8 mm or more with embryo transfer taking place 2 days later. RESULTS: The two groups were comparable with respect to cause of infertility, age at stimulation (32.8 ± 4 vs 33.2 ± 3.9 years, P = 0.4), basal FSH level (6.3 ± 1.7 vs 6.4 ± 2 IU/l, P = 0.5), number of oocytes collected (16.9 ± 7.3 vs 16.5 ± 7.4, P = 0.7) and fertilized normally in the retrieval cycle (11.5 ± 4.9 vs 11 ± 4.9, P = 0.4) and number of embryos cryopreserved (6.6 ± 3.6 vs 6.2 ± 3.6, P = 0.3). There was no significant difference between the two groups in age at frozen replacement (33.6 ± 4.2 vs 34 ± 3.9 years, P = 0.4), duration of the proliferative phase (20.7 ± 8.6 vs 21 ± 9.2 days, P = 0.7) and number of thawed embryos replaced (2.3 ± 0.6 vs 2.2 ± 0.6, P = 0.2). However, compared with group B, group A achieved significantly higher pregnancy (37.6% vs 24%, OR 1.8, 95%CI 1.1-3.4), clinical pregnancy (24% vs 11.3%, OR 2.5, 95%CI 1.2-5.5) and live birth rates (20% vs 8.5%, OR 2.9, 95%CI 1.2-8). CONCLUSION: Medicated frozen embryo replacement cycles timed by endometrial thickness measurement alone without monitoring or suppression of ovarian activity are associated with reduced outcome. Key words:
Key words: cryo-thawed cycle outcome/embryo cryopreservation/pituitary suppression
Accepted January 5, 2004
Article
Pituitary suppression in ultrasound-monitored frozen embryo replacement cycles. A randomised study
2 Assisted Conception Unit, 4th Floor Thomas Guy House, Guy’s Hospital, St. Thomas Street, London SE1 9RT, UK
3 Assisted Conception Unit, Guy’s and St. Thomas’ Hospital NHS Trust, London, UK; Department of Women’s Health, Guy’s, King’s and St. Thomas’ School of Medicine, St. Thomas Street, London SE1 9RT, UK
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. Griesinger, M. Weig, A. Schroer, K. Diedrich, and E.M. Kolibianakis Mid-cycle serum levels of endogenous LH are not associated with the likelihood of pregnancy in artificial frozen-thawed embryo transfer cycles without pituitary suppression Hum. Reprod., October 1, 2007; 22(10): 2589 - 2593. [Abstract] [Full Text] [PDF]
|
|